Today's story
Imfinzi Bladder Combo Wins FDA Priority Review
Up to half of muscle-invasive bladder cancer patients cannot take standard chemo. FDA gave Priority Review to AstraZeneca's IMFINZI-enfortumab combo for them; decision due Q4 2026.
Health · 10 sources · Sep 25, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About durvalumab
Durvalumab, sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. It was developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to programmed cell death ligand 1 (PD-L1) on cancer cells and blocks interactions with PD-1 and CD80 (B7.1) on T cells.
Everything about durvalumab →